Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of Low-dose Rituximab in the Treatment of Refractory Myasthenia Gravis

NCT05332587 is registered in ClinicalTrials.gov with First Affiliated Hospital, Sun Yat-Sen University as lead sponsor.

NCT NCT05332587
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05332587 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of Low-dose Rituximab in the Treatment of Refractory Myasthenia Gravis
Lead sponsor
First Affiliated Hospital, Sun Yat-Sen University
Phase
Phase 3
Overall status
Unknown status
Start date
August 1, 2020
Completion date
July 1, 2022
Enrollment
50 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

refractory myasthenia gravis, rituximab